/
India Pharmaceutical Cold Chain Logistics
Save to my account
Sign up
India Pharmaceutical Cold Chain Logistics
India Pharmaceutical Cold Chain Logistics
Study
1
Question
What is the current value of India's pharmaceutical industry in 2024?
Page 1
Answer
Around $52 billion, making it the third-largest by volume globally.
2
Question
How much of global generic drug production comes from India?
Page 1
Answer
About 10%.
3
Question
Why does cold chain logistics play a critical role in pharma?
Page 1
Answer
Nearly 20% of products require temperature-controlled environments to remain effective per WHO.
4
Question
What is the projected growth of India's pharma industry by 2030?
Page 1
Answer
$130 billion at 12% CAGR per IBEF.
5
Question
How have vaccines and biologics grown post-pandemic?
Page 1
Answer
Vaccines 15% increase, biologics 25% annually per IQVIA.
6
Question
What temperature range do vaccines require for storage?
Page 1
Answer
Strict control between 2–8°C; short exposure outside makes ineffective.
7
Question
How do biologics like insulin degrade?
Page 1
Answer
If temperatures exceed 8°C; often need -80°C storage and insulated packaging.
8
Question
What are global annual losses from cold chain failures?
Page 1
Answer
$35 billion.
9
Question
Why are Tier 2 cities a focus for cold chain in 2027-2028?
Page 1
Answer
Growing at 18% CAGR per McKinsey, expected 45% future demand per FICCI, but lack infrastructure.
10
Question
How do India's pharma exports show global importance?
Page 1
Answer
Crossed $27 billion in 2024 per Pharmexcil.
11
Question
What makes clinical trial materials challenging for cold chain?
Page 2
Answer
Both time-sensitive and temperature-sensitive; delays/deviations invalidate studies per CDSCO.
12
Question
What storage conditions suit retail pharma products like injectables?
Page 2
Answer
15–25°C, with humidity control to prevent clumping per FICCI.
13
Question
How tolerant are APIs and bulk drugs to temperature?
Page 2
Answer
Up to 30°C, but need dry conditions to prevent degradation per McKinsey.
14
Question
What governs pharma distribution in India?
Page 2
Answer
Good Distribution Practices (GDP) enforced by CDSCO under Drugs and Cosmetics Rules.
15
Question
What fine did companies face in 2024 for temp excursions?
Page 2
Answer
Over ₹10 crore.
16
Question
What US export regs require for cold chain?
Page 2
Answer
FDA under 21 CFR 211: validated systems, 7-year audit trails, stress-tested packaging.
17
Question
What 2023 FDA temp failures cost globally?
Page 3
Answer
$500 million losses.
18
Question
What annual compliance cost do companies face?
Page 3
Answer
Around ₹50 lakh on audits, training, sensor calibration.
19
Question
What spoilage rate hits vaccines and biologics?
Page 3
Answer
15–20% lost due to temp breaks, costing ₹8,000–10,000 crore annually.
20
Question
Why are export shipments vulnerable?
Page 3
Answer
Temp log issues lead to rejection in US/Europe, delaying payments/contracts.
21
Question
What causes lack of visibility in pharma supply chain?
Page 3
Answer
Tracking via phone calls/manual records leads to excess inventory, stockouts.
22
Question
How fragmented is the pharma distribution network?
Page 3
Answer
Highly fragmented with multiple intermediaries not coordinating, causing inaccurate forecasting.
23
Question
What limits profit margins in pharma?
Page 3
Answer
Government price controls on common medicines.
24
Question
What raw material issues do suppliers face?
Page 4
Answer
Quality/delivery delays cause production failures; imports from China expose to currency fluctuations.
25
Question
What operational challenges do distributors face?
Page 4
Answer
Temp control in transit, inventory balance (stockouts/overstock), last-mile in small towns lacks cold/refrig.
26
Question
What is the biggest structural gap in pharma supply chains?
Page 4
Answer
Systems not built for real-time, high-sensitivity logistics.
27
Question
How off are demand predictions typically?
Page 4
Answer
20–30%, leading to expiry or stockouts.
28
Question
What expiry management losses do distributors face yearly?
Page 5
Answer
₹50–100 lakh due to no automated alerts.
29
Question
Why is safety stock poorly calculated?
Page 5
Answer
Overstock to avoid shortages locks capital, increases expiry risk; no dynamic adjustment.
30
Question
What is batch-level traceability issue?
Page 5
Answer
Struggle to trace specific batch in recalls, delaying response/reg risk.